Objectives The aim of this study was to demonstrate feasibility and short-and midterm clinical outcomes with a new self-expanding transcatheter heart valve and motorized delivery system.
Transcatheter aortic valve replacement (TAVR) has been shown to reduce mortality in a randomized comparison with medical treatment (1) and to be noninferior to surgical aortic valve replacement in "high-risk operable" patients (2) . Further refinement of the procedure and current developments focus on minimizing access site complications, reducing stroke risk, improving paravalvular sealing, avoiding heart block, and facilitating easy and accurate prosthesis implantation. Some of these issues might be addressed by new delivery systems and transcatheter heart valves (THV). We report early experience with the CENTERA selfexpanding valve and a unique motorized delivery system (Edwards Lifesciences, Irvine, California).
Methods
The TAVR with the CENTERA THV was performed in 15 patients with symptomatic, severe aortic stenosis at 2 centers (St. Paul's Hospital, Vancouver, Canada, and the Asklepios Klinik St. Georg, Hamburg, Germany) between 2010 and 2012. All patients were considered at increased risk for surgery by a multidisciplinary team including cardiac surgeons and cardiologists, due to age, frailty, comorbidities, or technical issues (e.g., adherent coronary artery bypass grafts). All patients gave written informed consent for prospective data acquisition approved by the local ethics committee. Outcomes were reported according to the Valve Academic Research Consortium guidelines (3) and the Risk, Injury, Failure, Loss, and Endstage Kidney classification criteria (4) . Patients underwent pre-procedural aortic root, coronary and iliofemoral angiography, transthoracic echocardiography (TTE), and multidetector computed tomography (MDCT). Before discharge post-procedural TTE and MDCT were performed. The MDCTs were read by a single radiologist (J.L.) at St. Paul's Hospital. The TTEs were read at the local site. Clinical and echocardiographic follow-up was obtained at 30 days and 1 year. All data were prospectively collected in a dedicated database. Valve and delivery system. The CENTERA THV (Fig. 1) is composed of a self-expandable, radiopaque, nitinol stent; trileaflet bovine pericardial tissue valve (at annular level); and polyethylene terephthalate fabric. The delivery catheter is composed of an inner tubing assembly that contains the guidewire lumen, a torque shaft and delivery cylinder assembly, and an outer shaft (Fig. 2) . These are attached to a control handle (Fig. 3) . The guidewire lumen accommodates a 0.035-inch guidewire. The self-expanding THV is constrained in a metallic delivery cylinder. The catheter incorporates a deflection mechanism to assist in traversing the aortic arch and facilitate coaxial positioning within the native valve. The 26-mm CENTERA was indicated, according to the first-in-human protocol, if the aortic annulus measured 20 to 23 mm by transesophageal echocardiography (TEE) and the minimal internal lumen diameter of the access vessel was Ն5.5 mm.
The detachable handle (Fig. 3) is a battery-powered, motorized unit designed to provide sufficient torque to advance or retract the delivery cylinder when loading and deploying the THV. The handle has 2 buttons, allowing for either valve deployment (big button) or valve loading (small button). Procedure. The TAVR with the 26-mm CENTERA was performed under general anesthesia (10 patients) or local anesthesia (nϭ5) and fluoroscopy as well as TEE guidance. Patients were pre-medicated with aspirin and clopidogrel. An 18-F (initial 11 patients) or 16-F (last 4 transfemoral patients) sheath was introduced into the common femoral (nϭ11) or axillary artery (nϭ4) after pre-closure sutures were inserted percutaneously (ProStar for transaxillary patients or Perclose ProGlide for transfemoral patients, Abbott, Inc., Abbott Park, Illinois). The preferred access was transfemoral in Vancouver and trans-axillary in Hamburg. Pre-implant balloon aortic valvuloplasty was performed under rapid ventricular pacing in all cases. The delivery catheter was advanced over an Amplatz extra stiff 0.035- This self-expanding transcatheter heart valve incorporates a nitinol stent frame (expanded height 20 mm), a polyethylene terephthalate skirt, and bovine pericardial leaflets. Binder et al. New Self-Expanding Transcatheter Heart Valve inch guidewire (Cook, Inc., Bloomington, Indiana) into the left ventricle. Accurate positioning of the THV was ascertained by aortic root angiograms with a pigtail catheter and by TEE. Release of the THV was automatically performed by motorized retraction of the deployment cylinder. After the inflow and midportion of the THV were released and accurate positioning was confirmed, rapid ventricular pacing was initiated to facilitate final deployment of the THV (Fig.  4) . The valve position was documented by aortic root angiograms and TEE. The femoral or axillary access site was closed percutaneously. Patients were monitored for at least 72 h and discharged to continue on a regimen of low-dose aspirin and 3 months of daily clopidogrel (75 mg) unless oral anticoagulation was indicated. Statistical analysis. All analyses were performed with the SPSS software (version 17, SPSS, Inc., Chicago, Illinois). Continuous variables are expressed as mean values Ϯ SD. Categorical variables are described by frequencies and percentages. Comparisons of continuous variables were performed by a paired t test. All statistical tests were 2-tailed, and a value of p Ͻ 0.05 was considered statistically significant.
Results

Patients.
Baseline clinical characteristics are outlined in Table 1 . Clinical outcome. The CENTERA THV was successfully deployed in all 15 patients with a fully percutaneous approach. No patient required implantation of a second THV, and there were no cases of valve migration or embolization. In 1 patient the deployment was started too high above the annulus, and after partial deployment the THV was recaptured and immediately redeployed in the correct position. Five patients (33%) underwent intraprocedural post-dilation to address significant paravavular regurgitation (PAR). This reduced PAR to trace in 2 patients and mild in the remainder. One patient developed hemo-pericardium caused by pacing wire perforation, which was percutaneously drained. Complete heart block directly after valve deployment occurred in 4 patients (27%) and necessitated permanent pacemaker implantation. Moderateto-severe PAR was seen in 1 patient at discharge. He underwent post-dilation with a 25-mm balloon 30 days postprocedure, which reduced PAR to mild. Short-and midterm clinical outcomes are shown in Table 2 .
Survival was 87% (13 of 15) at 30 days and 80% (8 of 10) at 1-year follow-up. There were 2 in-hospital deaths, 1 due to a cardiac arrest complicating renal failure (hyperkalemia and volume overload) on Day 8, and a second due to in-hospital acquired pneumonia with respiratory failure on Day 23. A third later death occurred on Day 49 in a patient who was initially doing well and was urgently readmitted with sepsis. Autopsies were performed on all 3 patients. The deaths were found not to be valve-related (Fig. 5) . However, the 2 in-hospital deaths might be attributed to postprocedural complications. All patients, who were treated in 2010, were in New York Heart Association functional class I (2 patients, 25%) or II (6 patients, 75%) at 1-year follow-up (8 of 10 patients alive after 12 months). Echocardiography evaluation. Mean transaortic gradient was reduced from 36.3 Ϯ 14.2 mm Hg to 10.6 Ϯ 5.4 mm Hg The delivery catheter incorporates a hydrophilic outer shaft (A); a deflection area (B), which facilitates passage through aortic tortuosity and coaxial alignment within the annulus; the delivery cylinder (C), which restrains the valve in its crimped condition; and a tapered nose cone (D). The delivery system catheter outer diameter is 14-F. The cylinder that encapsulates the valve at the end of the delivery system has an outer diameter of 16-F. . The MDCT was performed in 6 patients post-TAVR (DynaCT, Siemens, Inc., Erlangen, Germany) (Fig. 6) . The MDCT is shown in Figure 7 . The area of the stent frame was 4.2 Ϯ 0.5 cm 2 at the inflow, 4.7 Ϯ 0.7 cm 2 in the midportion, and 5.2 Ϯ 0.6 cm 2 at the outflow. The THV eccentricity (1-short axis/long axis) at the inflow level was 18.7 Ϯ 10.9% and did not differ from annular eccentricity pre-TAVR 19.4 Ϯ 11.5% (p ϭ 0.903) (Fig. 7) . N S , V O L . 6 , N O . 3 , 2 0 1 3   M A R C H 2 0 1 3 : 3 0 1 -7 Binder et al.
The optimal deployment projection is the perpendicular view where all 3 cusps are separately depicted in a line (A). A balloon valvuloplasty is performed after crossing the aortic valve (B). The transcatheter heart valve inside the delivery catheter seen across the annulus (C). Accurate implant height of the partly deployed valve is ascertained by aortic root angiograms (D). Motorized retraction of the delivery sheath leads to self-expansion of the valve (E). After full deployment (F), the 3 connection points of the valve with the delivery system are released (G). Accurate position and paravalvular sealing is documented (H and J). J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O
New Self-Expanding Transcatheter Heart Valve
Discussion
We report the first-in-human experience with a new selfexpanding THV and motorized delivery system. A TAVR with the CENTERA THV and motorized delivery system was performed successfully in 15 patients with good hemodynamic and clinical short-and midterm outcomes.
The CENTERA THV design shares some similarities with current balloon-expandable THVs (SAPIEN and SAPIEN XT, Edwards Lifesciences). All incorporate bovine pericardial tissue leaflets and an internal polyethylene terephthalate paravalvular seal and use relatively "short" stent frames. The salient difference is the self-expanding nitinol frame, with a flared inflow, narrower annular segment, and a larger-diameter outflow. This shape is designed to facilitate self-seating in the aortic annulus. In comparison with most other self-expanding nitinol valves the CENTERA THV does not extend into the ascending aorta for anchoring or self-alignment.
The CENTERA fixation and alignment is dependent on the self-seating stent frame but also on a radically different delivery system. The motorized system is designed to improve the accuracy of deployment, without the high forces and uncertainty of manual unsheathing. Unlike other currently available systems, the THV does not tend to move axially during deployment, because it is fixed to the rigid inner catheter. The ability to flex the catheter contributes to accurate positioning. Although these design elements seem functional, the ability to position the THV coaxial to the annulus was markedly limited by the prototypic catheter system with a relatively long rigid distal segment. This might have resulted in suboptimal positioning, expansion, and sealing in the early experience. Recapture. Ideally a transcatheter valve would be optimally positioned on initial deployment; however, if positioning is suboptimal then the ability to recapture and reposition or retrieve would be a valuable option. The CENTERA valve incorporates features intended to assure correct positioning with the first attempt. However, it is apparent that further modification of the delivery catheter will be necessary to fully achieve this goal. Despite this, if initial valve deployment was suboptimal due to noncoaxial deployment, the CENTERA THV has a feature to allow easy recapture with the single hand operated motorized delivery system. This will be a possibility as long as the aortic end of the stent frame remains within the delivery cylinder. We used rapid ventricular pacing during final deployment. Whether this is necessary for stable THV release will be further studied. Stent frame geometry. Currently available balloon expandable stainless steel (SAPIEN) and cobalt chromium Values are mean Ϯ SD or n(%).
AVA ϭ aortic valve area; CABG ϭ coronary artery bypass graft; COPD ϭ chronic obstructive pulmonary disease; GFR ϭ glomerular filtration rate; LVEF ϭ left ventricular ejection fraction;
MDCT ϭ multidetector computed tomography; STS PROM ϭ Society of Thoracic Surgeons predicted risk of mortality; TAVR ϭ transcatheter aortic valve replacement; TEE ϭ transesophageal echocardiography; TTE ϭ transthoracic echocardiography; NYHA ϭ New York Heart Association functional class. (SAPIEN XT) frames generate a relatively high radial force and are generally circular despite the generally oval shape of the native aortic annulus (5). Self-expanding nitinol frames tend to generate a lower radial force and the inflow segment is more likely to be asymmetrical (6 -8) . In vitro testing has documented the potential for impaired hemodynamic performance and reduced durability with asymmetrical, noncircular valves (9) . It has been suggested that THV designs that incorporate supra-annular leaflets might mitigate against these concerns (7 Post-deployment 3-dimensional reconstruction of the transcatheter heart valve from a rotational aortic root angiogram (DynaCT, Siemens, Inc., Erlangen, Germany) allows appreciation of the prosthesis geometry and its position in the aortic root and annulus. Images from an 87-year-old patient who died of pneumonia 23 days post-implantation. Autopsy showed a well-seated bioprosthesis. The thrombi on the valve (A) were identified as postmortem clots. Stent struts were well-apposed to the left ventricular outflow tract and aortic root. The multidetector computed tomography eccentricity index of the native annulus was 36% (higher index indicating more oval shape). Eccentricity fell to 32% post-implant, which was appreciated on autopsy. The coronary ostia (B) were probed and documented unobstructed. Binder et al. New Self-Expanding Transcatheter Heart Valve Study limitations and future directions. These results represent the initial learning curve with very novel approaches to THV design and implantation. Modifications of the delivery system are planned to assure more reliable coaxial engagement of the native annulus, a limitation of this first-generation system. A reduced inflow diameter will be incorporated into the next-generation CENTERA THV with the goal, in part, to reduce mechanical stresses applied to the interventricular septum and conduction system (planed THV sizes 23, 26, and 29 mm). Further evaluation of the enhanced system is anticipated with a possible CE mark trial being completed by 2013.
